By Josh Beckerman

A diabetes drug being developed by Sanofi (SNY) and Lexicon Pharmaceuticals Inc. (LXRX) received a tie vote from a U.S. Food and Drug Administration advisory panel.

Before the 8-8 vote, Lexicon shares had been halted all day.

The FDA isn't required to follow the advice of such advisory panels, but it generally does so. An FDA decision is expected by March 22.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

January 17, 2019 19:12 ET (00:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.